Abstract
A retrospective cohort study was conducted in patients with type 2 diabetes in an electronic medical record database to compare real-world, 6-month glycated haemoglobin (HbA1c) and weight outcomes for exenatide once weekly with those for dulaglutide and albiglutide. The study included 2465 patients: exenatide once weekly, n = 2133; dulaglutide, n = 201; and albiglutide, n = 131. The overall mean (standard deviation [s.d.]) age was 60 (11) years and 54% were men; neither differed among the comparison groups. The mean (s.d.) baseline HbA1c was similar in the exenatide once-weekly (8.3 [1.7]%) and dulaglutide groups (8.5 [1.5]%; P = .165), but higher in the albiglutide group (8.7 [1.7]%; P < .001). The overall mean (s.d.) HbA1c change was -0.5 (1.5)% (P < .001) and this did not differ among the comparison groups in either adjusted or unadjusted analyses. The mean (s.d.) weight change was -1.4 (4.7) kg for exenatide once weekly and -1.6 (3.7) kg for albiglutide (P = .579), but was greater for dulaglutide, at -2.7 (5.7) kg (P = .001). Outcomes were similar in subsets of insulin-naive patients with baseline HbA1c ≥7.0% or ≥9.0%. All agents significantly reduced HbA1c at 6 months, with no significant differences among agents or according to baseline HbA1c in insulin-naive subgroups.
Keywords:
GLP-1; database research; dulaglutide; exenatide; glycaemic control; type 2 diabetes.
© 2017 John Wiley & Sons Ltd.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Body Mass Index
-
Cohort Studies
-
Diabetes Mellitus, Type 2 / blood
-
Diabetes Mellitus, Type 2 / complications
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Drug Administration Schedule
-
Exenatide / administration & dosage*
-
Exenatide / adverse effects
-
Exenatide / therapeutic use
-
Female
-
Follow-Up Studies
-
Glucagon-Like Peptide 1 / administration & dosage
-
Glucagon-Like Peptide 1 / adverse effects
-
Glucagon-Like Peptide 1 / analogs & derivatives*
-
Glucagon-Like Peptide 1 / therapeutic use
-
Glucagon-Like Peptide-1 Receptor / agonists*
-
Glucagon-Like Peptide-1 Receptor / metabolism
-
Glucagon-Like Peptides / administration & dosage
-
Glucagon-Like Peptides / adverse effects
-
Glucagon-Like Peptides / analogs & derivatives*
-
Glucagon-Like Peptides / therapeutic use
-
Glycated Hemoglobin / analysis
-
Humans
-
Hyperglycemia / prevention & control*
-
Hypoglycemia / prevention & control
-
Hypoglycemic Agents / administration & dosage*
-
Hypoglycemic Agents / adverse effects
-
Hypoglycemic Agents / therapeutic use
-
Immunoglobulin Fc Fragments / administration & dosage*
-
Immunoglobulin Fc Fragments / adverse effects
-
Immunoglobulin Fc Fragments / therapeutic use
-
Male
-
Middle Aged
-
Obesity / complications
-
Recombinant Fusion Proteins / administration & dosage*
-
Recombinant Fusion Proteins / adverse effects
-
Recombinant Fusion Proteins / therapeutic use
-
Retrospective Studies
-
Weight Loss / drug effects
Substances
-
GLP1R protein, human
-
Glucagon-Like Peptide-1 Receptor
-
Glycated Hemoglobin A
-
Hypoglycemic Agents
-
Immunoglobulin Fc Fragments
-
Recombinant Fusion Proteins
-
hemoglobin A1c protein, human
-
rGLP-1 protein
-
Glucagon-Like Peptides
-
Glucagon-Like Peptide 1
-
Exenatide
-
dulaglutide